Mucolytic agent
For anyone who requires a liquid / dispersible product acetylcysteine will be first line as branded Acepiro and can be prescribed for anyone.
Carbocisteine capsules can be prescribed for anyone who can swallow capsules.
Carbocisteine liquid is non-formulary
Prescribe by brand Acepiro as per local TLS arrangements
| Pack | Price |
|---|---|
| 20 tablet (2 x 10 tablets) | £3.65 |
| 30 tablet (5 x 6 tablets) | £5.25 |
Mucolytic
Assess response to treatment after 4 weeks and continue therapy at
maintenance dose if a satisfactory response has been achieved.
Stop therapy at 6 weeks if no benefit.
For anyone who requires a liquid / dispersible product acetylcysteine will be first line as branded Acepiro and can be prescribed for anyone.
Carbocisteine capsules can be prescribed for anyone who can swallow capsules.
Carbocisteine liquid is non-formulary
| Pack | Price |
|---|---|
| 120 capsule | £2.82 |
Acetylcysteine AKA N-Acetylcysteine Capsules and Tablets
Idiopathic pulmonary fibrosis
NICE CG163 Idiopathic pulmonary fibrosis in adults: diagnosis and management
| Pack | Price |
|---|---|
| 30 capsule | £85.00 |
| Pack | Price |
|---|---|
| 30 tablet |
| Pack | Price |
|---|---|
| 30 tablet |
| Pack | Price |
|---|---|
| 30 sachet | £112.50 |
Respiratory disorders associated with thick, viscous, mucus hypersecretion
| Pack | Price |
|---|---|
| 30 sachet | £112.50 |
Carbocisteine Oral Solution
Mucolytic
Only prescribe if Acepiro is not tolerated
Assess response to treatment after 4 weeks and continue therapy at
maintenance dose if a satisfactory response has been achieved.
Stop therapy at 6 weeks if no benefit.
| Pack | Price |
|---|---|
| 125 ml | |
| 250 ml | |
| 300 ml | £7.55 |
| Pack | Price |
|---|---|
| 300 ml | £6.16 |
Treatment of cystic fibrosis in people aged ≥6 years who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator gene
Rationale 1,6
Cystic Fibrosis
Brand: Pulmozyme
Rationale: 1,6
| Pack | Price |
|---|---|
| 30 ampoule | £496.43 |
| 6 ampoule |
| Pack | Price |
|---|---|
| 30 ampoule | £496.43 |
Cystic fibrosis
Rationale: 1,2
Clinical Commissioning Policy 16049/P
April 2017
Updated advice:
NHS England has confirmed that ivacaftor, tezacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor will be made available as treatment options for people with cystic fibrosis who have one of an expanded range of CFTR mutations within the set criteria.
NHS England commissioning statement.
March '21.
Cystic Fibrosis with transmembrane conductance regulator (CFTR) mutations
Rationale 1,6
NHS England has confirmed that ivacaftor, tezacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor will be made available as treatment options for people with cystic fibrosis who have one of an expanded range of CFTR mutations within the set criteria.
Elexacaftor/ivacaftor/tezacaftor for patients aged 12 years and above who have two F508del mutations or one F508del and a minimal function (MF) mutation
Cystic Fibrosis in people 12 years and older who are homozygous for the F508del mutation.
Rationale 1,6
NHS England has confirmed that ivacaftor, tezacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor will be made available as treatment options for people with cystic fibrosis who have one of an expanded range of CFTR mutations within the set criteria. NHS England commissioning statement. March '21.
Symptomatic treatment of acute exacerbations of chronic bronchitis
Rationale: 3